Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
5(45%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
2
18%
Ph phase_2
9
82%

Phase Distribution

2

Early Stage

9

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
9(81.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

11

all time

Status Distribution
Active(8)
Completed(2)
Other(1)

Detailed Status

Recruiting4
Not yet recruiting3
Completed2
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
5
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (18.2%)
Phase 29 (81.8%)

Trials by Status

active_not_recruiting19%
not_yet_recruiting327%
recruiting436%
completed218%
unknown19%

Recent Activity

5 active trials
Showing 5 of 11
recruitingphase_2

Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC

NCT07309952
not_yet_recruitingphase_2

A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors

NCT07448922
recruitingphase_2

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

NCT07098988
not_yet_recruitingphase_2

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

NCT07432594
not_yet_recruitingphase_2

Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

NCT07234058
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07309952Phase 2

Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC

Recruiting
NCT07448922Phase 2

A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors

Not Yet Recruiting
NCT07098988Phase 2

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Recruiting
NCT07432594Phase 2

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

Not Yet Recruiting
NCT07234058Phase 2

Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

Not Yet Recruiting
NCT06771622Phase 1

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Active Not Recruiting
NCT07245446Phase 2

A Study of Ivonescimab in First-Line ES-SCLC

Recruiting
NCT07178171Phase 1

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

Recruiting
NCT04177953Phase 2

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

Completed
NCT05244837Phase 2

Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC

Unknown
NCT01160744Phase 2

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11